- Home
- XPON vs QNRX Comparison
XPON vs QNRX Comparison
Compare XPON & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- QNRX
- Stock Information
- Founded
- XPON 2016
- QNRX 2018
- Country
- XPON United States
- QNRX United States
- Employees
- XPON N/A
- QNRX N/A
- Industry
- XPON Electronic Components
- QNRX Medical/Dental Instruments
- Sector
- XPON Technology
- QNRX Health Care
- Exchange
- XPON Nasdaq
- QNRX Nasdaq
- Market Cap
- XPON 3.2M
- QNRX 3.3M
- IPO Year
- XPON 2022
- QNRX N/A
- Fundamental
- Price
- XPON $0.83
- QNRX $9.60
- Analyst Decision
- XPON
- QNRX
- Analyst Count
- XPON 0
- QNRX 0
- Target Price
- XPON N/A
- QNRX N/A
- AVG Volume (30 Days)
- XPON 46.9K
- QNRX 12.9K
- Earning Date
- XPON 08-13-2025
- QNRX 08-07-2025
- Dividend Yield
- XPON N/A
- QNRX N/A
- EPS Growth
- XPON N/A
- QNRX N/A
- EPS
- XPON N/A
- QNRX N/A
- Revenue
- XPON $6,702,411.00
- QNRX N/A
- Revenue This Year
- XPON $61.26
- QNRX N/A
- Revenue Next Year
- XPON N/A
- QNRX N/A
- P/E Ratio
- XPON N/A
- QNRX N/A
- Revenue Growth
- XPON 23.07
- QNRX N/A
- 52 Week Low
- XPON $0.60
- QNRX $5.01
- 52 Week High
- XPON $120.00
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- XPON 43.08
- QNRX 64.78
- Support Level
- XPON $0.81
- QNRX $8.04
- Resistance Level
- XPON $0.97
- QNRX $8.58
- Average True Range (ATR)
- XPON 0.08
- QNRX 0.46
- MACD
- XPON -0.01
- QNRX 0.04
- Stochastic Oscillator
- XPON 18.57
- QNRX 98.57
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.